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Analternatingcopolymerofstyreneandmaleicacid(alt-PSMA)diﬀersfromotherpolyanionicantiviralagentsinthatthenegative
charges of alt-PSMA are provided by carboxylic acid groups instead of sulfate or sulfonate moieties. We hypothesized that alt-
PSMA would have activity against human immunodeﬁciency virus type 1 (HIV-1) comparable to other polyanions, such as the
related compound, poly(sodium 4-styrene sulfonate) (PSS). In assays using cell lines and primary immune cells, alt-PSMA was
characterized by low cytotoxicity and eﬀective inhibition of infection by HIV-1 BaL and IIIB as well as clinical isolates of subtypes
A, B, and C. In mechanism of action assays, in which each compound was added to cells and subsequently removed prior to
HIV-1 infection (“washout” assay), alt-PSMA caused no enhancement of infection, while PSS washout increased infection 70%
above control levels. These studies demonstrate that alt-PSMA is an eﬀective HIV-1 inhibitor with properties that warrant further
investigation.
1.Introduction
Polyanionic molecules were shown to be eﬀective inhibitors
of the human immunodeﬁciency virus type 1 (HIV-1),
not long after the recognition of HIV-1 as the viral agent
responsible for the acquired immune deﬁciency syndrome
(AIDS). Dextran sulfate and heparin were two of the ﬁrst
sulfated compounds identiﬁed as compounds with antiviral
activities against HIV-1 [1, 2]. Polyanionic molecules are
generallyconsideredtobeentryinhibitors,withtheactivities
of these compounds stemming from their abilities to inhibit
virus adsorption to the surface of the target cell membrane
[3]. The main mechanism of action associated with this
family of compounds involves electrostatic interactions with
HIV-1 gp120. Interactions between these negatively charged
molecules and the positively charged V3 loop of gp120
interfere with receptor-mediated binding and inhibit host
cellinfection[4–6].Itwasalsoestablishedthattheiractivities
were dependent on the level of sulfation, with two sulfate
groups per monosaccaride required to achieve maximal
anti-HIV-1 activity [3]. These studies demonstrated that
the negative charges on these polymeric molecules play
important roles in inhibition of HIV-1 infection.
A number of polyanionic compounds and their formu-
lations have been developed as inhibitors of HIV-1 binding
and entry [7, 8]. Among these are PRO 2000 (naphtha-
lene 2-sulfonate polymer) [9], PSS [poly(sodium 4-styrene
sulfonate] [10], HPMCT (hydroxypropyl methylcellulose
trimellitate) [11], and CAP (cellulose acetate phthalate) [4].
These compounds have been evaluated in preclinical studies
or have been advanced into clinical trials for their use in
microbicides,whichareproductsdesignedtoreduceorelim-
inate the risk of HIV-1 sexual transmission [7, 12]. Although
they have distinct chemical formulae, these compounds
have three common structural and chemical characteristics:
(i) they are polymeric in nature (high molecular weight);
(ii) they possess a level of hydrophobicity associated with
incorporated ring structures; (iii) they bear multiple anionic2 Journal of Biomedicine and Biotechnology
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Figure 1: Structures of alt-PSMA and PSS. (a) alt-PSMA (120,000
average MW) is a readily synthesized copolymer of styrene and
maleic acid that incorporates two carboxylic groups and a phenyl
group in each repeating unit. (b) The structure of poly(sodium 4-
styrene sulfonate) (PSS), which includes a single, sulfated phenyl
ring in each repeat unit, is shown for comparison.
charges along the length of the molecule. These charac-
teristics (particularly the anionic charges) presumably play
roles in deﬁning the biological activities of these molecules,
speciﬁcally their capacities to inhibit infection by HIV-1 and
other enveloped viruses and their eﬀects on cellular viability.
We hypothesized that a molecule with similar structural
characteristics would have comparable activity against HIV-
1. Poly(styrene-alt-maleic acid) is an alternating copolymer
(alt-PSMA) comprised of styrene and maleic acid at a 1 : 1
ratio. Like PRO 2000, PSS, HPMCT, and CAP, alt-PSMA is
characterizedbythepresenceofmultipleanionicchargesand
hydrophobic, aromatic rings (Figure 1(a)). However, in alt-
PSMA (120,000 average MW), the hydrophobic phenyl side
group, contributed by the styrene unit, is directly attached to
the hydrocarbon backbone. In addition, unlike the sulfated
or sulfonated molecules PSS (Figure 1(b)), PRO 2000, or
carrageenan [13], alt-PSMA derives its anionic charge from
two free carboxyl groups (pKa 1.9 and 6.0) of maleic acid,
whicharealsodirectlyattachedtothehydrocarbonbackbone
instead of the aromatic ring.
The properties of alt-PSMA prompted an exploration
of the antiviral potential of this polyanionic molecule. In
vitro assays of compound cytotoxicity and antiviral activity
demonstrated that alt-PSMA combines low cytotoxicity
with considerable antiviral activity against R5 and X4
viruses of multiple subtypes. Furthermore, in washout assays
typically used to explore compound mechanism of action
and examine compound residence time after removal from
target cells, alt-PSMA had no impact on subsequent HIV-1
infection, whereas PSS caused increased levels of infection.
These experiments compare and contrast alt-PSMA with
other polyanionic compounds and provide the foundation
for the further development of alt-PSMA as an inhibitor of
HIV-1 infection.
2.MaterialsandMethods
2.1. Compounds. alt-PSMA (catalog no. 662631, lot
71K1378) and dextran sulfate (DS; Dextralip 50, catalog no.
D8787, lot 71K1378) were purchased from Sigma-Aldrich
(St. Louis, MO). Polystyrene sulfonate (PSS, lot DFS-1951)
was kindly provided by National Starch and Chemical
Company (Chattanooga, TN).
2.2. Cell Line Maintenance and Primary Cell Isolation.
P4-R5 MAGI cells (NIH AIDS Research and Reference
Reagent Program # 3580) were maintained in Dulbecco’s
Modiﬁed Eagle’s Media (DMEM) supplemented with 10%
fetal bovine serum (FBS), sodium bicarbonate (0.05%),
antibiotics (penicillin, streptomycin, and kanamycin at
40μg/mL each), and puromycin (1μg/mL) [14]. TZM-bl
cells (NIH AIDS Research and Reference Reagent Program
# 8129) were maintained in Dulbecco’s Modiﬁed Eagle’s
Media (DMEM) supplemented with 10% fetal bovine
serum (FBS), sodium bicarbonate (0.05%), and antibiotics
(penicillin, streptomycin, and kanamycin at 40μg/mL each)
[15]. Human peripheral blood mononuclear cells (PBMCs)
were isolated from whole blood (Biological Specialty Corp.,
Colmar, PA) using Ficoll-hypaque (Amersham Biosciences,
Piscataway, NJ) density gradient centrifugation and were
subsequently cultured in RPMI supplemented with 10%
FBS,sodiumbicarbonate(0.05%),antibiotics(penicillinand
streptomycin at 90μg/mL each), PHA-P (Sigma-Aldrich;
5μg/mL), and IL-2 (NIH AIDS Research and Reference
Reagent Program # 11697; 20U/mL) [16]. After 48h, the
PBMCs were washed and incubated for an additional 24h
in the absence of PHA-P prior to infection.
2.3. Propagation of Primary HIV-1 Clinical Isolates. PBMCs
(4×107 cellsstimulatedasdescribedabove)weretreatedwith
polybrene (Sigma-Aldrich) at a concentration of 2μg/mL
for 30min. The cells were then pelleted and 1mL of virus
stock was used to resuspend the cells. Cells and virus
were incubated at 37
◦Cw i t h5 %C O 2 f o r2 hw i t hg e n t l e
mixing every 30min. After the incubation interval, the
cells were washed two times with PBMC media. The cells
were again pelleted and subjected to a second incubation
with virus (1mL). Following the second incubation, the
cells were again washed and resuspended in PBMC media
(10mL) supplemented with 2μg/mL of polybrene (co-
culture media), and the volume was equally divided into two
T-75 ﬂasks. An additional 25mL of media was added to each
ﬂask. The cultures were assessed for p24 content on days 3
through 7 postinfection, and cells were split whenever the
p24 level exceeded 100ng/mL. On day 7, the cell suspension
was clariﬁed by centrifugation twice, initially at 1400rpm for
10min at 4◦C, followed by centrifugation of the supernatant
at 2400rpm for 10min at 4◦C. After clariﬁcation, the viral
suspension was aliquoted and stored at −85
◦C until use. The
clinical isolates (all R5 coreceptor phenotypes obtained from
the NIH AIDS Research and Reference Reagent Program)
included two strains of subtype A (KNH1144, catalog no.
112460; KNH1207, catalog no. 11247) [17], one strain of
subtype B (US1, catalog no. 7686) [18–20], and two subtype
C strains (93MW965, catalog no. 2913; SM145, catalog no.
7697) [18–20].
2.4. Assessing alt-PSMA Inhibition of Infection by Cell-Free
HIV-1. P4-R5 MAGI cells were cultured at a density of 1.2×
104 cells/well in a 96-well plate 18h prior to infection. CellsJournal of Biomedicine and Biotechnology 3
were incubated for 2h with HIV-1 laboratory strains BaL or
IIIB (Advanced Biotechnologies Inc., Columbia, MD) in the
absence or presence of alt-PSMA or DS. After 2h, cells were
washed, cultured for an additional 46h, and subsequently
assayed for HIV-1 infection using the Galacto-Star β-
Galactosidase Reporter Gene Assay System for Mammalian
Cells (Applied Biosystems, Bedford, MA). In a variation of
this experiment, cell-free virus was preincubated with alt-
PSMAorDSfor10minat37
◦C,followedbya1:100dilution
of the virus : compound mixture in complete RPMI media
and addition to P4-R5 MAGI cells.
2.5. Assessing alt-PSMA Inhibition of Infection by Cell-
Associated HIV-1. alt-PSMA was evaluated for its ability
to inhibit infection by HIV-1 IIIB-infected Sup-T1 T
lymphocytes. Compounds were incubated with 1×105 HIV-
1 IIIB-infected SupT1 cells for 10min followed by a 1:10
dilution in RPMI media and incubation for 2h with P4-R5
MAGI cells at a density of 8 × 104 cells/well in a 12-well
plate. In a variation of this experiment, mitomycin-treated
HIV-1 IIIB-infected SupT1 cells (0.2mg/mL mitomycin
C for 30min) were incubated with compounds for 2min
followed by a 1:10 dilution in RPMI media and incubation
for 2h with P4-R5 MAGI cells. Cells were then washed
and incubated for 46h and assessed for β-galactosidase
production as described above.
2.6. Evaluating In Vitro Cytotoxicity of alt-PSMA. P4-R5
MAGI cells were seeded at a density of 4 × 104 cells/well in
a 96-well plate approximately 18h prior to experiment. Cells
were then exposed to the indicated concentrations of alt-
PSMA or DS for 10min, 2h, or 24h. Following the exposure
period, cells were washed and assessed for viability using a
3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bro-
mide(MTT)assayofviability[21,22].ForPBMCs,cellswere
seeded at a density of 1 × 105 cells/well in a 96-well plate.
Cells were then exposed to the indicated concentrations of
alt-PSMA, PSS, or DS for 6h (to mirror the duration of
compound exposure in the antiviral assay). Following the
exposure period, cells were washed and assessed for via-
bility using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme-
thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) as-
say of viability [23, 24]. CC50 values (concentration at which
exposure to the compound resulted in a 50% decrease in
cellviabilityrelativetomock-treatedcells)weresubsequently
calculated from the results.
2.7. Demonstrating HIV-1 Inhibition by alt-PSMA in Pri-
mary Human Immune Cells. Human PBMCs, stimulated as
described above, were seeded at a density of 1×105 cells/well
ina96-wellplate.Cellswerethenincubatedfor6hwithHIV-
1 BaL or IIIB in the absence or presence of alt-PSMA, PSS, or
DS. After 6h, cells were washed and subsequently cultured
for 3 days, at which time the cells were washed and supplied
with new media supplemented with IL-2. The cells were
then incubated for an additional 3 days and subsequently
assayed for HIV-1 production by determining the level of
p24 core antigen in the supernatant using an HIV-1 p24
antigen ELISA assay (ZeptoMetrix, Buﬀalo, NY). Levels of
infection were expressed relative to mock-treated, HIV-1-
infected cells.
2.8. Demonstrating alt-PSMA Eﬃcacy against Subtype A, B,
and C Clinical Isolates. TZM-bl cells were cultured at a
density of 1.2 × 104 cells/well in a 96 well plate 18h prior
to infection. Cells were incubated for 2h with HIV-1 clinical
isolates in the absence or presence of alt-PSMA or PSS.
After 2h, cells were washed, cultured for an additional 46h,
and subsequently assayed for HIV-1 infection using the
Galacto-Star β-Galactosidase Reporter Gene Assay System
for Mammalian Cells (Applied Biosystems, Bedford, MA).
2.9. Evaluating the Eﬀects of Compound Washout on HIV-
1I n f e c t i o n .IC90 concentrations for inhibition of cell-free
HIV-1 infection by alt-PSMA, PSS, or DS were determined
using procedures as described above, except that the infec-
tion duration was shortened to 1h. In the washout assay, P4-
R 5M A G Ic e l l sw e r ei n c u b a t e dw i t hI C 90 concentrations of
compound for 1h. Cells were then washed extensively, pro-
vided with new media without compound, and then infected
at 2h or 4h after compound removal with HIV-1 BaL or IIIB
for 1h at 37
◦C. As a control, compound, virus, and cells were
incubated together for 1h. Following infection, cells were
washed again, provided with media without compound, and
assayed 46h postinfection as described above.
2.10. Data Analyses. Data for all experiments are shown as
mean values and calculated standard deviations from two
independent assays in which each concentration was exam-
ined in triplicate. Calculations of IC50/IC90 concentrations
(concentrations that resulted in 50% or 90% decreases in
infection relative to mock-treated, HIV-1-infected cells) and
CC50 concentrations (concentrations that resulted in a 50%
reduction in cell viability relative to mock-exposed cells)
were calculated using the Forecast function of Microsoft
Excel.
3. Results
3.1. alt-PSMA Is an Eﬀective Inhibitor of Infection by HIV-1
BaL. In the context of microbicide development, the impor-
tance of inhibiting infection by R5 viruses is underscored
by the prevalence of R5 variants early in infection and the
presumed preference for R5 viruses during the process of
HIV-1 transmission [8, 25]. Experiments were conducted
to determine the ability of alt-PSMA to inhibit infection
by HIV-1 BaL, which has an R5 phenotype (Figure 2(a)).
alt-PSMA was an eﬀective inhibitor of infection, achieving
complete inhibition at 0.1mg/mL and above and an IC50
value of 0.009mg/mL during 2h incubation with virus
and P4-R5 MAGI cells. Similar experiments, in which cell-
free HIV-1 BaL and compounds were incubated for 10min
prior to introduction to the target P4-R5 MAGI cells, were
conducted to determine the direct eﬀect of each compound
on virus infectivity. A 10-min preincubation of cell-free
virus with alt-PSMA followed by 1:100 dilution of the4 Journal of Biomedicine and Biotechnology
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Figure 2: alt-PSMA inhibits infection by HIV-1 strains BaL and
IIIB. P4-R5 MAGI cells were incubated for 2h with HIV-1 strains
(a) BaL or (B) IIIB in the absence or presence of alt-PSMA or
DS (as described in Section 2). For the preincubation portion
of the experiment, compound and virus were ﬁrst incubated for
10min prior to dilution and addition to cells. Infectivity remaining
was expressed relative to mock-treated, HIV-1-infected cells and
graphed against the compound concentration achieved during the
2-h incubation. Each concentration was examined in triplicate in
two independent assays.
virus : compound mixture prior to addition to cells had
no impact on the ability of alt-PSMA to inhibit infection
by HIV-1 BaL. These and subsequent experiments also
included the control compound DS, which was used as
a prototypical polyanionic compound with high antiviral
activity and low cytotoxicity. When compared to DS (IC50
value of 0.03mg/mL), alt-PSMA appeared to be modestly
more eﬀective against HIV-1 BaL. Preincubation of DS with
cell-free virus had no impact on its antiviral activity.
3.2. Preincubation of alt-PSMA with HIV-1 IIIB Enhances
Its Antiviral Activity. Similar experiments were performed
using the X4 HIV-1 strain IIIB (Figure 2(b)). Relative
to its activity against HIV-1 BaL, alt-PSMA had slightly
higher inhibitory activity against HIV-1 IIIB (IC50 value
of 0.005mg/mL). Similar diﬀerences in coreceptor usage-
dependent activity have been demonstrated using other
polyanions, including PSS [26]a n dH P M C T[ 11]. Interest-
ingly, a 10-min preincubation of alt-PSMA with cell-free
HIV-1 IIIB resulted in an approximately 6-fold increase in
antiviralactivity(IC50 =0.0008mg/mL)relativetoitsactivity
in the absence of preincubation (IC50 = 0.005mg/mL). In
contrast, the antiviral activity of DS (IC50 = 0.0006mg/mL)
was unaﬀected by preincubation (IC50 = 0.0005mg/mL).
3.3. alt-PSMA Inhibits Infection by HIV-1-Infected T Lym-
phocytes. Since inhibitors and potential microbicide agents
must also be eﬀective against cell-associated infectivity,
experiments were conducted to demonstrate the ability
of alt-PSMA to inhibit infection by HIV-1-infected cells
(Figure 3). Infection of P4-R5 MAGI target cells by HIV-
1 IIIB-infected Sup-T1 T lymphocytes (Figure 3(a))w a s
inhibited in a dose-dependent manner by alt-PSMA (IC50
= 0.03mg/mL). Inhibition by DS was comparable (IC50 =
0.01mg/mL). Additionally, to look solely at the ability of
alt-PSMA to inhibit viral transfer from infected cells [27],
mitomycin C-treated HIV-1 IIIB-infected SupT1 cells were
used as the source of infectivity. alt-PSMA again inhibited
infection in a dose-dependent manner (IC50 = 0.12mg/mL)
comparable to that of DS (Figure 3(b)).
3.4. alt-PSMA Is Characterized by Low In Vitro Cytotoxicity.
In vitro cytotoxicity experiments were performed to deter-
mine the eﬀect of alt-PSMA on cellular viability, to evaluate
the potential safety of alt-PSMA, and to demonstrate that
compound cytotoxicity had no impact on the results of
the antiviral assays. Exposures to alt-PSMA for 10min
or 2h had no eﬀect on P4-R5 MAGI cell viability at
concentrations at or below 3.16mg/mL (Figure 4(a)). After
a 24-h exposure to alt-PSMA, P4-R5 MAGI cell viability
was reduced only at the highest concentration (62% viability
at 3.16mg/mL). Similarly, cell viability was reduced by
exposure to DS only after a 24-h exposure at the highest
concentration examined (Figure 4(b)). These results indicate
that (i) the demonstrated antiviral eﬃcacy of alt-PSMA was
not aﬀected by changes in target cell viability, since alt-
PSMA exposure was not cytotoxic at the concentrations and
exposuredurationsusedintheantiviralexperiments;(ii)alt-
PSMA may have a considerable margin of safety, with an in
vitro therapeutic index (CC50/IC50) in excess of 350.
3.5. HIV-1 Infection of Primary Human PBMCs Is Inhib-
ited by alt-PSMA. In vitro experiments were also used
to demonstrate the ability of alt-PSMA to inhibit HIV-
1 infection of primary human immune cell populations
(Figure 5). Secondarily, these experiments provided a com-
parison between alt-PSMA and PSS, which are similar in
that both compounds have repeating anionic charges and
aromatic rings along their backbones. In experiments in
which PBMCs were infected by HIV-1 BaL (Figure 5(a)),Journal of Biomedicine and Biotechnology 5
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Figure 3:alt-PSMAinhibitsinfectionofP4-R5MAGIcellsbyHIV-
1-infected cells. (a) HIV-1 strain IIIB-infected Sup-T1 T cells were
incubated for 10min in the absence or presence of alt-PSMA or
DS prior to 1:10 dilution and incubation with P4-R5 MAGI cells
for 2h (as described in Section 2). (b) Mitomycin C-treated HIV-
1 strain IIIB-infected Sup-T1 T cells were incubated for 2min in
the absence or presence of alt-PSMA or DS prior to 1:10 dilution
and incubation with P4-R5 MAGI cells for 2h (as described in
Section 2). Infectivity remaining was expressed relative to mock-
treated, HIV-1-infected cells and graphed against the compound
concentration achieved during the 2-h incubation with P4-R5
MAGI cells. Each concentration was examined in triplicate in two
independent assays.
inhibition of infection by alt-PSMA (IC50 = 0.02mg/mL)
was concentration-dependent and comparable to levels
of inhibition achieved in the presence of PSS (IC50 =
0.04mg/mL) or DS (IC50 = 0.04mg/mL). Similar experi-
ments using HIV-1 IIIB (Figure 5(b)) demonstrated that alt-
PSMA (IC50 = 0.003mg/mL), PSS (IC50 = 0.002mg/mL),
and DS (IC50 = 0.005mg/mL) again had similar capacities
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Figure 4: alt-PSMA has low in vitro cytotoxicity similar to DS. P4-
R5 MAGI cells were exposed (or mock-exposed) to the indicated
concentrations of (a) alt- P S M Ao r( b )D Sf o r1 0m i n ,2h ,o r2 4h .
Following the exposure period, cells were washed and assessed
for viability using an MTT assay (as described in Section 2).
Results illustrated are from two independent assays in which each
concentration was examined in quadruplicate.
for inhibiting HIV-1 infection. Again, all three compounds
were approximately one log more eﬀective against HIV-1
IIIB compared to their activities against BaL. In assays of
in vitro cytotoxicity using PBMCs, all three compounds
were noncytotoxic (Figure 5(c)) at concentrations shown
to inhibit HIV-1 infection, with CC50 values of 9.1mg/mL
for alt-PSMA and in excess of 10mg/mL for PSS and DS.
These results indicated that alt-PSMA and PSS, which have
similar structural features (anionic charge, aromatic rings),
have similar capacities for inhibiting HIV-1 infection. Fur-
thermore, these results demonstrated, at least in the context
of this experimental design, that the identity (carboxylic or6 Journal of Biomedicine and Biotechnology
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Figure 5: alt-PSMA eﬀectively inhibits infection of primary human immune cells by HIV-1 strains BaL and IIIB. PBMCs were incubated for
6hwithHIV-1strains(a)BaLor(b)IIIBintheabsenceorpresenceofalt-PSMA,PSS,orDS(asdescribedinSection 2).Infectivityremaining
is expressed relative to mock-treated, HIV-1-infected cells. Each concentration was examined in triplicate in two independent assays. (c)
PBMCs were exposed (or mock exposed) to the indicated concentrations of alt-PSMA, PSS, or DS for 6h. Following the exposure period,
cells were washed and assessed for viability using an MTS assay (as described in Section 2). Results illustrated are from two independent
assays in which each concentration was examined in triplicate.
sulfonic acid) or position (backbone or aromatic ring) of the
anionic charge had no apparent eﬀect on antiviral activity
and a negligible eﬀe c to ni nv i t r oc y t o t o x i c i t y .
3.6. HIV-1 Clinical Isolates of Various Subtypes Are Inhibited
by alt-PSMA. To be eﬀective in the context of the global
HIV/AIDS epidemic, inhibitors of HIV-1 infection must
have antiviral activity against the range of regional HIV-
1 subtypes found throughout the world. To this end, alt-
PSMA was evaluated for its activities against clinical isolates
from subtypes A, B, and C. These isolates included two
subtype A strains (KNH1144 and KNH1207), one subtype
B virus (US1), and two strains from subtype C (93MW965
and SM145). In antiviral assays using TZM-bl indicator cells,
alt-PSMA was an eﬀective inhibitor of all viral subtypes
examined, with IC50 concentrations ranging from 0.003 to
0.009mg/mL (Table 1). Furthermore, alt-PSMA appeared to
be more eﬀective against the subtype A and B isolates com-
pared to PSS; PSS IC50 concentrations were approximately
4- to 7-fold higher against these three isolates relative to the
IC50 concentrations of alt-PSMA.
3.7. alt-PSMA Washout Does Not Aﬀect HIV-1 Infection,
While PSS Washout Enhances Infection. A washout assay, in
which antiviral compounds are removed from cells or tissues
prior to HIV-1 infection, can be used to explore compoundJournal of Biomedicine and Biotechnology 7
Table 1: alt-PSMA and PSS activity (IC50/IC90) against clinical isolates of various subtypes.
Virus identiﬁer (subtype)a,b
93MW965 (C) SM145 (C) KNH1144 (A) KNH1207 (A) US1 (B)
PSMA 0.009/0.03 0.006/0.05 0.005/0.02 0.003/0.02 0.003/0.009
PSS 0.003/0.2 0.004/0.3 0.02/0.09 0.02/0.03 0.02/0.09
aAll viruses were characterized as R5, as described in the NIH AIDS Research and Reference Reagent Program datasheets.
bAntiviral activities are expressed as IC50/IC90 concentrations (mg/mL).
mechanism of action or, in the case of an agent that acts on
or in the host cell, examine compound residence time after
removal from the culture medium. Preparative assays used
to establish IC50 and IC90 concentrations for alt-PSMA, PSS,
and DS during a 1-h infection demonstrated that all three
compounds were eﬀective HIV-1 inhibitors, with IC50 values
againstBaLof0.009mg/mL,0.04mg/mL,and0.0058mg/mL
and IC50 values against IIIB of 0.003mg/mL, 0.01mg/mL,
and 0.00052mg/mL for alt-PSMA, PSS, and DS, respectively.
InthewashoutassaysusingIC90 concentrationsofeachcom-
pound, co-incubation of compound, cells, and HIV-1 BaL
(Figure 6(a)) or IIIB (Figure 6(b)) produced the expected
results: approximately 90% inhibition of each virus was
achieved. In contrast, removal of alt-PSMA and subsequent
infectionbyeithervirusat2hor4haftercompoundremoval
had no eﬀect on HIV-1 infection (compared to cells infected
in the absence of compound). Since polyanionic compounds
have been shown to inhibit HIV-1 infection by interactions
with gp120 [5, 6, 28–33], abrogation of the inhibitory eﬀects
of PSMA and DS by compound washout was anticipated,
sincethecompoundswerenotavailabletobindtogp120and
thus inhibit viral binding and entry.
Unexpectedly, PSS washout caused increases in HIV-1
infection dependent on time of infection and coreceptor
usage by the infecting virus. HIV-1 BaL infection after PSS
washout was increased by approximately 39% over controls
at the 2-h time point but unaﬀected by 4-h postwashout.
In contrast, HIV-1 IIIB infection was persistently enhanced
at both 2h (55% increase) and 4h (67% increase) after
PSS removal. These results suggest functional interactions
between PSS and host cells that serve to enhance HIV-1
infection and/or replication. In addition, these experiments
provide a clear functional distinction between alt-PSMA and
PSS despite their structural similarities.
4. Discussion
These in vitro studies conﬁrmed the opening hypothesis,
which stated that alt-PSMA would be an eﬀective inhibitor
of HIV-1 infection as a consequence of its gross structural
similaritiestotheanti-HIV-1compoundPSS[10].alt-PSMA
was shown to have equipotent activities against laboratory-
adapted R5 and X4 HIV-1 strains, activity against cell-free
and cell-associated virus, demonstrable antiviral activity in
the context of HIV-1 infection of primary human immune
cells, and activity against a range of HIV-1 subtypes. The
activity of alt-PSMA against HIV-1, which we ﬁrst reported
at the 2005 International Meeting of the Institute of Human
Virology [34], was recently conﬁrmed in structure-activity
studies of poly(styrene-alt-maleic anhydride) derivatives
[35]. Presumably, alt-PSMA inhibits HIV-1 attachment and
entry in a manner comparable to PSS [26]. The speciﬁc
mechanism of action of alt-PSMA, like polyanionic dextran
sulfate, likely involves electrostatic interactions with the V3
loop and coreceptor binding site [6].
Demonstrated diﬀerences, however, between alt-PSMA
and other polyanionic compounds, particularly in the com-
pound washoutexperiments,suggestedthatsubtlestructural
diﬀerences between these compounds may be functionally
importantunderspeciﬁcconditions.Despitegeneralsimilar-
ities between members of the polyanionic compound family,
alt-PSMA is distinguished from PSS and other polyanionic
molecules by three charge-related characteristics. First, the
anionic charges of alt-PSMA are provided by carboxylic
groups instead of the sulfonate side groups found on PSS
(charge identity). Second, the negatively charged carboxylic
groups of alt-PSMA are located on the backbone and are
separated from the hydrophobic phenyl side chains of the
styrene moiety (charge location). In contrast, the negatively
charged sulfonate group of PSS is itself a side group of
the styrene repeat unit (Figure 1). Similarly, the sulfonate
group of PRO 2000, which provides its anionic charge,
is a side chain of the naphthalene ring that is part of
the polymeric structure [9]. Third, alt-PSMA includes two
anionic charges per repeat instead of the single anionic side
group found in each repeat of PSS (charge density). As
previously shown, diﬀerences in the number of charges per
repeat unit, which aﬀect the linear charge density of the
molecule,canimpactantiviralactivity[3].Thesedistinctions
in charge identity, location, and density may be important
factors in diﬀerentiating alt-PSMA from other polyanionic
molecules. The present studies provide the starting point
for future structure-function experiments that will examine
the eﬀects of charge identity, placement, and density on
compound activity and will provide new insights into the
mechanisms that underlie the eﬃcacy and safety of this
family of compounds.
Results of these investigations also indicated that vari-
ations in antiviral eﬃcacy were evident not only as a
consequence of diﬀerences in inhibitors, but also because of
diﬀerences between infecting viruses and between target cell
types. For example, the diﬀerential eﬀect of virus-compound
preincubation (Figures 2(a) and 2(b)) on antiviral activity
indicated both compound- and virus-speciﬁc diﬀerences in
inhibitorretentiononcell-freevirions.Speciﬁcally,enhanced
antiviral activity against HIV-1 IIIB but not BaL following
alt-PSMA preincubation with virus may be attributed to
the more basic nature of X4 gp120 molecules [6], which8 Journal of Biomedicine and Biotechnology
would theoretically promote increased compound retention
on the virus surface. Furthermore, because of fundamental
diﬀerences in backbone structure between alt-PSMA and
DS, this mechanism of electrostatic retention of DS may not
be possible. In addition, assays using PBMCs as target cells
(Figure 5) demonstrated that alt-PSMA, PSS, and DS were
more eﬀective inhibitors of HIV-1 IIIB (X4) relative to their
activities against the R5 strain BaL. Similar diﬀerences in
antiviral activity were previously reported in assays involving
the polyanions PSS [26]a n dH P M C T[ 11]. Diﬀerences
in antiviral activity related to coreceptor usage could be
attributed to the more basic nature of the X4 gp120 V3
region [6], which may promote a greater electrostatic aﬃnity
for anionic inhibitors and, thus, greater antiviral eﬃcacy.
However, this eﬀect may be oﬀset by other factors (such
as host cell type), since alt-PSMA had equipotent activity
against BaL and IIIB in experiments using P4-R5 MAGI
cells as hosts for infection. In addition, diﬀerences in eﬃcacy
against viruses that diﬀer in subtype but not in coreceptor
usage (Table 1) suggested that other genotypic or phenotypic
diﬀerences between viruses aﬀect antiviral eﬃcacy.
Assaysinvolvingcompoundwashouthaverevealedapre-
viously unknown activity of selected polyanionic molecules.
The unexpected enhancement of HIV-1 infection by PSS
suggested an activity that involves perturbation of the host
cell, since, in this type of assay, only the target cells are
exposed to signiﬁcant concentrations of the compound. This
activity appeared to compound-speciﬁc, since neither alt-
PSMA nor DS produced this eﬀect. In the context of the
experimental design, two possible mechanisms of PSS action
are suggested. First, low levels of PSS may be retained on the
cell surface despite extensive cell washing. This explanation
appears to be consistent with a previous report of enhanced
HIV-1 infection at low concentrations of the polyanionic
compound cellulose sulfate [36]. At low cellulose sulfate
concentrations that are insuﬃcient to provide antiviral
activity, mechanisms that enhance HIV-1 infection might be
unmasked. In a similar fashion, the removal of PSS from
the media and the retention of small amounts of PSS on
the cell surface may have caused enhanced HIV-1 infection.
However, the mechanisms at work in these situations
may be similar but not identical, since the magnitude of
enhancement in the washout assays was considerably higher
(Figure 6 and Pirrone and Krebs, manuscript in preparation)
than increases in infection observed at low compound
concentrations [36]. In either case, low concentrations of
compound on the cell surface may eﬀect changes on the cell
surface that facilitate the binding and entry steps of the HIV-
1 replication cycle.
Alternatively,enhancedHIV-1infectionmaybetheresult
of intracellular changes initiated by interactions between PSS
and the cell surface. For example, incubation with PSS may
activate signaling pathways that aﬀect HIV-1 gene expres-
sion. Cellular activation mediated by transient exposure to
PSSwouldpersistforseveralhoursandwouldnotrequirethe
continued presence of PSS. Interestingly, there is precedence
for this type of activity among polyanionic HIV-1 inhibitors.
Previous studies have shown that activation of macrophages
by λ-carrageenan, which is used to induce nonspeciﬁc
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Figure 6: alt-PSMA washout does not increase HIV-1 BaL or
IIIB infection. P4-R5 MAGI cells were incubated for 1h with
predetermined IC90 concentrations of alt-PSMA (0.03mg/mL, BaL;
0.02mg/mL, IIIB), PSS (0.1mg/mL, BaL; 2.29mg/mL, IIIB), or DS
(0.031mg/mL, BaL; 0.0028mg/mL, IIIB). Following exposure, cells
were washed thoroughly, provided with new media for 2h or 4h,
and subsequently infected with HIV-1 strains BaL (a) or IIIB (b) for
1h. As a control, compound, virus, and cells were simultaneously
incubated for 1h (labeled “S” on each graph). Levels of infection
are expressed relative to mock-treated, HIV-1 infected cells. Each
concentrationwasexaminedintriplicateintwoindependentassays.
The asterisk (∗) indicates a signiﬁcant diﬀerence compared to
infected, mock-exposed control cells (P ≤ .001).
inﬂammation in murine models of footpad edema and
pleurisy, was dependent on toll-like receptor 4 (TLR4)
and the downstream factor MyD88 [37]. Cellular signaling
pathways, such as those activated by TLR stimulation, may
stimulate HIV-1 gene expression through NF-κB-mediated
activation of the HIV-1 long terminal repeat (LTR) [38].
Enhancement of HIV-1 infection by select polyanionic
compounds may be relevant to microbicide clinical trials,Journal of Biomedicine and Biotechnology 9
particularly to the failure of Ushercell (cellulose sulfate) in
recent trials [39, 40]. Because the cervicovaginal environ-
ment is open, microbicide products can leak out over time.
For example, in clinical trials involving Ushercell, compound
leakage was reported by female users, and product leakage
had a negative eﬀect on product acceptability [41, 42].
In a scenario in which product leakage has suﬃciently
reduced the concentration of the active compound (i.e.,
cellulose sulfate) within the cervicovaginal environment,
HIV-1 transmission may be enhanced rather than inhibited.
ThiseﬀectcouldexplaintheincreasedriskofHIV-1infection
associated with Ushercell use in one of two clinical trials
[39, 40].
To date, the clinical failures of cellulose sulfate, car-
rageenan, and PRO 2000, despite clear demonstrations of in
vitro eﬃc a c ya n di nv i v os a f e t y ,h a v en o tb e e ns a t i s f a c t o r i l y
explained. Two reports that presented possible explanations
for the failures of two of these compounds [36, 43]w e r e
published after their respective clinical trials had been
initiated. In light of the results of washout experiments
described above, our own studies were expanded to include
other polyanionic HIV-1 inhibitors. We demonstrated using
cell lines as well as primary human immune cells that
other polyanionic molecules, including cellulose sulfate
and carrageenan, also enhanced HIV-1 infection if the
compounds were removed prior to the introduction of virus
(Pirrone and Krebs, manuscript in preparation) [44]. In
these experiments, demonstrated levels of enhancement in
primaryimmunecellsequaledorexceededlevelsofenhance-
ment achieved in the HeLa-based P4-R5 MAGI indicator
cell line. We also demonstrated that enhancement of HIV-1
infection was dependent on a number of variables, including
compound identity and concentration, time of application
with respect to HIV-1 infection, and coreceptor usage.
5. Conclusions
In light of the clinical failures of polyanionic molecules such
as dextran sulfate [45], cellulose sulfate [40, 46], carrageenan
[47], and PRO 2000 [48, 49], a shift away from any further
investigations focused on polyanionic HIV-1 inhibitors as
drug or microbicide candidates might be perceived as
an appropriate course of action. However, the beneﬁts
of continued studies of these compounds should not be
overlooked. Studies of existing polyanion HIV-1 inhibitors
may contribute to a better understanding of the clinical
failures of these compounds and provide much-needed links
between preclinical investigations and clinical trials. In a
similar manner, studies of new and eﬀective polyanionic
inhibitors,suchasalt-PSMA,mayfurtherourunderstanding
of these agents. Finally, continued studies may provide useful
information about molecular structures and charge charac-
teristics that should be incorporated into future generations
of HIV-1 inhibitors destined for systemic or microbicide use.
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